Vaishali Pharma initiates registration of 30 products in Central African countries
Vaishali Pharma Limited has informed the bourses that it has initiated registration of 30 products in the Central African Countries with a portfolio of antibiotics, sedatives, anti-malaria, anti-inflammatory, painkillers, and multi-vitamins.
These products have a good demand in the markets of Central African countries. This will enable the company to strengthen its presence in the high growth market of Central African Countries and reach out to more territories. It also plans to register a similar range of products in the neighbouring countries.
The value of Africa’s pharmaceutical industry jumped to USD 20.8 billion in 2013 from just USD 4.7 billion, a decade earlier. This growth is constantly progressing at a rapid pace and experts predict that the market will be worth USD 40-65 billion by 2020 and so on.
In the month of March 2021, the company had been awarded two tenders for the supply of surgical & pharma products to Vanuatu Islands along with the supply of surgical products to Samoa Islands.
Vaishali Pharma is one of the leading players in the supply of pharma products, bulk drugs/APIs, formulations, surgical products, veterinary supplements, herbal & nutraceutical products, etc. It has built a robust pipeline of around 250 dossiers.
At 10.39 am on Friday, the stock of Vaishali Pharma was trading 3.02 per cent higher at Rs 34.10 from its previous close of Rs 33.10 on NSE.